AJP - Heart Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 289: H2012-H2019, 2005. First published July 1, 2005; doi:10.1152/ajpheart.00495.2005
0363-6135/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/5/H2012    most recent
00495.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleegal, M. A.
Right arrow Articles by Davis, T. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fleegal, M. A.
Right arrow Articles by Davis, T. P.

Activation of PKC modulates blood-brain barrier endothelial cell permeability changes induced by hypoxia and posthypoxic reoxygenation

Melissa A. Fleegal,1 Sharon Hom,1,2 Lindsay K. Borg,1 and Thomas P. Davis1,2

1Department of Medical Pharmacology and 2Program in Physiological Sciences, The University of Arizona, Tucson, Arizona

Submitted 13 May 2005 ; accepted in final form 28 June 2005


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The blood-brain barrier (BBB) is a metabolic and physiological barrier important for maintaining brain homeostasis. The aim of this study was to determine the role of PKC activation in BBB paracellular permeability changes induced by hypoxia and posthypoxic reoxygenation using in vitro and in vivo BBB models. In rat brain microvessel endothelial cells (RMECs) exposed to hypoxia (1% O2-99% N2; 24 h), a significant increase in total PKC activity was observed, and this was reduced by posthypoxic reoxygenation (95% room air-5% CO2) for 2 h. The expression of PKC-{beta}II, PKC-{gamma}, PKC-{eta}, PKC-µ, and PKC-{lambda} also increased following hypoxia (1% O2-99% N2; 24 h), and these protein levels remained elevated following posthypoxic reoxygenation (95% room air-5% CO2; 2 h). Increases in the expression of PKC-{epsilon} and PKC-{zeta} were also observed following posthypoxic reoxygenation (95% room air-5% CO2; 2 h). Moreover, inhibition of PKC with chelerythrine chloride (10 µM) attenuated the hypoxia-induced increases in [14C]sucrose permeability. Similar to what was observed in RMECs, total PKC activity was also stimulated in cerebral microvessels isolated from rats exposed to hypoxia (6% O2-94% N2; 1 h) and posthypoxic reoxygenation (room air; 10 min). In contrast, hypoxia (6% O2-94% N2; 1 h) and posthypoxic reoxygenation (room air; 10 min) significantly increased the expression levels of only PKC-{gamma} and PKC-{theta} in the in vivo hypoxia model. These data demonstrate that hypoxia-induced BBB paracellular permeability changes occur via a PKC-dependent mechanism, possibly by differentially regulating the protein expression of the 11 PKC isozymes.

protein kinase C; paracellular; neurovascular unit; rat

THE BLOOD-BRAIN BARRIER (BBB) is a metabolic and physiological barrier important for maintaining cerebral homeostasis. Brain microvessels that form the BBB are lined with specialized endothelial cells surrounded by pericytes, astroglial processes, and the extracellular matrix. Compared with the peripheral microvasculature, cerebral microvessels are highly specialized because they lack vesicular transport and fenestrations while having a high level of metabolic activity. This lack of fenestrations is due to the presence of tight junctions (TJ) and adherens junctions, which restrict paracellular movement of molecules across the BBB (29, 31, 40).

Stroke is a leading cause of death and disability in the United States (3). It has been demonstrated that the BBB is compromised during stroke (29). The effects of stroke on the cerebral vasculature significantly contribute to the brain damage caused by stroke. It has been determined that the lack of oxygen (hypoxia, H) followed by reperfusion (posthypoxic reoxygenation, H/R) during stroke contributes to both neuronal and vascular damage. Both H and H/R cause increases in cerebrovascular permeability with concomitant increases in vasogenic cerebral edema (1, 36, 47).

Previous studies (36, 47) have demonstrated that H and H/R cause changes in paracellular permeability to [14C]sucrose in cerebral vascular endothelial cells. These permeability changes have been correlated with alterations in the expression and localization of several TJ proteins (36). More recently, nitric oxide (NO) and Ca2+ have been shown to partially mediate the effects of H and H/R on cellular permeability, though the mechanisms by which NO and Ca2+ may cause these permeability changes are still unclear (17, 35). However, it has recently been suggested that phosphorylation of the TJ proteins can affect the functionality of the TJ (4, 23, 33, 46). Several intracellular signaling molecules have been shown to regulate TJ protein phosphorylation, including tyrosine kinases, MAPK, and PKC (4, 33).

Recently, studies (28, 30) have begun to investigate the mechanisms by which the different PKC isozymes (conventional, {alpha}, {beta}I, {beta}II, {gamma}; novel, {delta}, {epsilon}, {theta}, {eta}, µ; and atypical, {lambda} {zeta}) regulate the expression and function of the TJ proteins. These studies have shown that the activities of the various PKC isozymes have diverse effects on the function and the integrity of epithelial cell barriers. For example, activation of PKC-{delta}, PKC-{lambda}, and PKC-{theta} is detrimental to the cytoskeletal structure and permeability of the intestinal epithelial barrier, whereas activation of PKC-{zeta} protects the integrity of this barrier (5, 6, 12).

Whether these effects of PKC activation also occur in endothelial cells at the BBB remains to be determined. There is increasing evidence that PKC alters BBB permeability by altering TJ function. Pertussis toxin increases permeability of the cerebral endothelial cells in vitro via a PKC-dependent pathway (19). Desai et al. (21) demonstrated that endothelial barrier dysfunction caused by interleukin-6 was mediated via PKC. Finally, studies (49) have also shown that PKC-{alpha} and PKC-{beta} are both involved in regulating endothelial cell permeability after ischemia and inflammatory stimulation.

However, it remains to be determined whether the ischemic stressors H and H/R actually stimulate upregulation of PKC activity in endothelial cells of the BBB. Furthermore, it is unknown whether this PKC activation is involved in H- and H/R-induced BBB paracellular permeability changes. The goal of this study was to determine whether H- and H/R-mediated changes in BBB permeability involve increased PKC activity and protein expression in BBB endothelial cells. This was investigated with both an in vitro tissue culture model and a global, nonocclusive in vivo H model. The data presented demonstrate that H and H/R regulate PKC activity in BBB endothelial cells and that PKC is involved in H-induced changes in BBB paracellular permeability. Additionally, this study demonstrates that the expression of the PKC isozymes is differentially regulated following both H and H/R in each of our BBB models.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Chemicals and supplies. Plasma-derived horse serum (PDHS), MEM, Ham's F-12 nutrient mixture, gentamicin, amphotericin B, heparin sodium, polymyxin B, and anti-rabbit peroxidase-conjugated secondary antibody were all purchased from Sigma (St. Louis, MO). Rabbit anti-PKC-{alpha}, rabbit anti-PKC-{beta}I, rabbit anti-PKC-{beta}II, rabbit anti-PKC-{gamma}, rabbit anti-PKC-{delta}, rabbit anti-PKC-{epsilon}, rabbit anti-PKC-{eta}, rabbit anti-PKC-µ, rabbit anti-PKC-{theta}, rabbit anti-PKC-{zeta}, and rabbit anti-PKC-{lambda} were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Complete Mini Protease Inhibitor and Complete Mini EDTA-free Protease Inhibitor were purchased from Roche Applied Science (St. Louis, MO). Nitrocellulose and 10% Tris·HCl Criterion gels were purchased from Bio-Rad Laboratories (Hercules, CA). [{gamma}-32P]ATP and Western Lighting Chemiluminescence Reagent Plus were purchased from New England Nuclear/PerkinElmer Life Sciences (Boston, MA). The PKC Activity Assay kit was purchased from Calbiochem (La Jolla, CA). All other chemicals and supplies were purchased from Sigma.

Animals. Sprague-Dawley rats were purchased from Harlan (Indianapolis, IN). Rats were housed individually in 12-h light-controlled facilities. Animals were fed ad libitum and had free access to water. All procedures were approved by the University of Arizona Institutional Animal Use and Care Committee.

RMEC isolation. Brains were removed from male and female Sprague-Dawley rats (250–300 g), and rat brain microvessel endothelial cells (RMECs) were isolated by using a modified method of Miller et al. (38). Briefly, microvessels were isolated from rat cortical gray matter using a sequence of enzymatic digestions and differential centrifugations, and cells were then suspended in MEM containing Ham's F-12 nutrients (45%), PDHS (10%), gentamicin (50 µg/ml), amphotericin B, and heparin sodium. Cells were plated at 50,000 cells/cm2 on collagen/fibronectin-coated dishes or 0.4 µM Transwell filters. Cells were fed 3 days after the initial plating and fed every 2 days afterward. The confluent cells were then used between days 11 and 14.

In vitro H treatment. Confluent RMEC monolayers were treated under hypoxic conditions using a temperature- and oxygen-controlled hypoxia workstation infused with 1% O2-99% N2 at 37°C for 24 h. After the H treatment, a subset of RMECs was then incubated at 37°C for 2 h in 95% room air-5% CO2 for the H/R treatment. For controls, RMECs were treated with room air for 24 h. After treatment, the monolayers were then used to measure PKC activity, to measure [14C]sucrose permeability, or for Western blot analysis of PKC isozymes.

In vivo H treatment. As described previously (47), male or female Sprague-Dawley rats (200–250 g) were anesthetized with intraperitoneal injections (1 ml/kg) consisting of ketamine (78.3 mg/ml) and xylazine (3.1 mg/ml) and acepromazine (10 mg/ml) before treatment. Physiological body temperature was maintained using a heating pad. For H treatment, rats were placed in an oxygen-controlled hypoxia chamber at 6% O2-94% N2 for 1 h. For H-treated rats, the brain was removed in the workstation chamber. For H/R treatment, rats were removed from the H chamber and placed in room air for 10 min. After H/R treatment, the brain was removed. As a control, rats were anesthetized and placed in room air for 1 h. After treatment and removal of the brains, cerebral microvessels were isolated and analyzed for PKC activity and protein expression of PKC isozymes.

Rat cerebral microvessel isolation. Brain microvessels were isolated from rat cerebral gray matter for analysis of PKC activity and protein expression. Rats were anesthetized and treated as stated above. After removal of the brain, it was immersed in ice-cold buffer A containing (in mM) 103 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, and 15 HEPES (pH 7.4), and the meninges and choroid plexus were removed. The cortical mantles were weighed and then homogenized in a Teflon homogenizer in a fivefold volume of buffer B containing (in mM) 103 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, 15 HEPES, 25 NaHCO3, 10 glucose, sodium pyruvate, and dextran (MW 64,000, 1 g/100 ml), pH 7.4 (Complete Mini Protease Inhibitor). After homogenization, an equal volume of 26% dextran was added, and the sample was centrifuged at 5,800 g at 4°C for 10 min. The supernatant was discarded, the pellet was resuspended in 10 ml of buffer B, and the suspension was then passed through a 100-µm mesh. The filtrate was centrifuged at 500 g for 5 min, and the pellet was resuspended in 1 ml of buffer B. The sample was centrifuged again at 14,000 rpm for 5 min at 4°C, and the pellet was resuspended in PKC extraction buffer containing (in mM) 25 Tris·HCl (pH 7.4), 0.5 EDTA, 0.5 EGTA, and 10 {beta}-mercaptoethanol, and Triton X-100 (0.05%), leupeptin (1 µg/ml), and aprotinin (1 µg/ml). The sample was centrifuged a second time at 14,000 rpm for 5 min at 4°C, and the supernatant was saved and stored at –80°C.

PKC activity assay. Total PKC activity in treated RMECs or isolated rat microvessels was measured by using the PKC Assay kit from Calbiochem. The protocol established by the company was used with slight modifications. Briefly, PKC was isolated from treated RMECs or isolated rat cerebral microvessels (RCMV) using PKC extraction buffer containing (in mM) 25 Tris·HCl (pH 7.4), 0.5 EDTA, 0.5 EGTA, and 10 {beta}-mercaptoethanol, and Triton X-100 (0.05%), leupeptin (1 µg/ml), and aprotinin (1 µg/ml). The sample containing PKC was then incubated with a PKC substrate and [{gamma}-32P]ATP for 30 min at 37°C. The enzymatic reaction was terminated, and free avidin solution was added to the mixture. After a series of washes and centrifugations, avidin-bound biotinylated 32P-labeled peptide was removed. Samples were counted to determine the amount of radioactivity incorporated by the PKC. Specific activity [in pmol phosphate·min–1·sample amount–1 (SA)] was calculated as follows

where SA is the amount of PKC sample in microliters, cpm(r) is the reference sample count in counts per minute, cpm(e + s) is the reaction sample count for the PKC sample, cpm(e) is the reaction sample count for the sample minus substrate, and t is the incubation period time.

[14C]sucrose permeability assay. The paracellular flux across the RMEC monolayer was determined as described previously (36). After treatment, the growth medium was replaced with assay buffer containing (in mM) 122 NaCl, 3 KCl, 1.4 CaCl2, 1.2 MgSO4, 25 NaHCO3, 10 HEPES, 10 glucose, and 0.5 K2HPO4 for 30 min at 37°C. Initially, 0.5 µCi of [14C]sucrose was added to the upper chamber (lumen). Immediately, 50 µl of solution were removed from the upper chamber to determine the initial concentration of [14C]sucrose. Samples (50 µl) were then removed from the lower chamber (abluminal) at times 0, 30, 60, and 120 min, and 50 µl of fresh assay buffer were added at each time. At the conclusion of the experiment, the amount of radioactivity in each sample was determined, and paracellular flux of [14C]sucrose across the membrane at 30, 60, and 120 min was calculated by using the following equation:

where V is the volume in the receiver chamber (1.5 ml), SA is the surface area of the monolayer (1 cm2), Cd is the concentration of [14C]sucrose in the donor chamber at time 0, and Cr is the concentration of [14C]sucrose in the receiving chamber at either 30, 60, or 120 min. To determine the permeability coefficient, flux was plotted versus time, and the permeability coefficient (cm/min) was calculated by using linear regression analysis in Microsoft Excel.

Western blot analysis. SDS-PAGE and Western blot analysis were done as described previously (25). Briefly, proteins were separated on 10% Tris·HCl gels and transferred to nitrocellulose. The appropriate positive controls for each PKC isozyme were run alongside samples to ensure that the correct PKC isoform was being detected by each antibody. PKC-{alpha}, PKC-{beta}I, PKC-{beta}II, PKC-{gamma}, PKC-{delta}, PKC-{epsilon}, PKC-{eta}, PKC-{lambda}, PKC-µ, PKC-{theta}, and PKC-{zeta} were detected by chemiluminescence using rabbit anti-PKC-{alpha} (1:3,000), rabbit anti-PKC-{beta}I (1:1,000), rabbit anti-PKC-{beta}II (1:15,000), rabbit anti-PKC-{gamma} (1:10,000), rabbit anti-PKC-{delta} (1:5,000), rabbit anti-PKC-{epsilon} (1:10,000), rabbit anti-PKC-{eta} (1:1,000), rabbit anti-PKC-µ (1:1,000), rabbit anti-PKC-{theta} (1:15,000), rabbit anti-PKC-{zeta} (1:2,000), and rabbit anti-PKC-{lambda} (1:1,000) and horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:16,000). After being exposed to films, all nitrocellulose membranes were washed and stained with India ink for normalization of protein loading. Films and membranes were scanned by using the Kodak Image Station, and semiquantifiable analysis of the protein was done by using the Kodak 1D Imaging Software (Eastman Kodak, New Haven, CT).

Statistical analysis. All experiments were repeated at least three times, and all data are means ± SE. All statistical analysis was done by using Sigma Stat software. All activity and permeability data were analyzed using one-way ANOVA, followed by the Student-Newman-Keuls t-test. RMEC PKC activity data were also analyzed using a t-test to compare normoxia and H treatments. RMEC protein expression was analyzed using one-way ANOVA, followed by Bonferroni's t-test. RCMV protein expression was analyzed using one-way ANOVA, followed by Fisher least significant difference test.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
BBB endothelial cell PKC activity in vitro after H and H/R. The first series of experiments investigated the activation of PKC after H and H/R in an in vitro BBB model. In RMECs treated with H (1% O2-99% N2; 24 h), total PKC activity increased by 73% compared with that of normoxia (95% room air-5% CO2; 24 h)-treated controls (Fig. 1). After H/R (95% room air-5% CO2; 2 h), there was a reduction in total PKC activity in RMECs back toward normoxia levels (Fig. 1). This increase in PKC activity correlates with previous studies (1, 36, 47), demonstrating that exposure to H increases [14C]sucrose permeability.



View larger version (10K):
[in this window]
[in a new window]
  		Fig. 1. Hypoxia (H) stimulates total PKC activity in vitro. Confluent monolayers of cultured RMECs were exposed to normoxia (N), hypoxia (1% O2-99% N2; 24 h), or hypoxia followed by 2 h of posthypoxic reoxygenation (H/R), and PKC activity was determined as described in MATERIALS AND METHODS. Graph shows means ±SE for treatment conditions. *P < 0.05 compared with N (n = 13).

 
PKC isozyme expression in RMECs after H and H/R. In the next set of experiments, we determined whether the expression of the PKC isozymes was altered during H and H/R in the in vitro BBB model. Based on previous studies (17) which demonstrated a role for Ca2+ in the H- and H/R-mediated changes on endothelial cell permeability, we first investigated the effects of H and H/R on the expression of the Ca2+-dependent PKCs (conventional) in RMECs. After treatment with H (1% O2-99% N2; 24 h), there was a significant increase in the expression of the PKC-{beta}II and PKC-{gamma} (Fig. 2A) in RMECs. The expression levels of both PKC-{beta}II and PKC-{gamma} remained elevated after 2 h of H/R (95% room air-5% CO2; Fig. 2A). There was no effect of H or H/R on the expression of PKC-{alpha} and PKC-{beta}I (Table 1) in RMECs.



View larger version (68K):
[in this window]
[in a new window]
  		Fig. 2. Hypoxia and posthypoxic reoxygenation alter protein expression of conventional, novel, and atypical PKC isozymes in RMECs. Confluent monolayers of cultured RMECs were exposed to normoxia (N, room air, 24 h), hypoxia (H, 1% O2-99% N2; 24 h), or hypoxia followed by 2 h of posthypoxic reoxygenation (H/R, room air), and protein expression was measured using Western blot analysis. Representative Western blot analysis showing expression of the conventional PKC isozymes (A; {alpha}, {beta}I, {beta}II, and {gamma}), novel PKC isozymes (B; µ, {epsilon}, {eta}, {delta}, and {theta}), and atypical PKC isozymes (C; {zeta} and {lambda}) after treatment conditions. Table 1 summarizes data from all Western blot analyses.

 

View this table:
[in this window]
[in a new window]
  		Table 1. Effects of H and H/R on protein expression of conventional, novel, and atypical PKC isozymes in RMECs in vitro.

 
Recent evidence (6) in the literature also suggests a role for the novel and atypical PKCs (Ca2+ independent) in modulating endothelial cell permeability. In RMECs treated with H (1% O2-99% N2; 24 h), there was a significant increase in the expression of the novel PKCs, PKC-{eta}, and PKC-µ (Fig. 2B; Table 1), and the expression of these two PKC isozymes remained elevated following 2 h of reoxygenation. After H/R (95% room air-5% CO2; 2 h), there was a significant increase in the expression of PKC-{epsilon} (Fig. 2B; Table 1), which was not seen after hypoxic treatment. Both H and H/R had no significant effect on the expression of PKC-{theta} or PKC-{delta} (Table 1) in RMECs. In addition, there were also changes in the protein expression of the atypical PKCs. After H (1% O2-99% N2; 24 h) in RMECs, an increase in the expression of PKC-{lambda} protein was observed, and the protein levels of PKC-{lambda} remained elevated during H/R (Fig. 2C; Table 1). Meanwhile, the protein expression of PKC-{zeta} was slightly reduced after H but then significantly increased above hypoxic levels after H/R (Fig. 2C).

Role of PKC in H- and H/R-induced paracellular permeability changes. Similar to previous studies (1, 36), there was an effect of oxygen concentration on paracellular permeability in BBB endothelial cells. Compared with normoxia treatment (room air; 24 h), H (1% O2-99% N2; 24 h) caused a significant increase (129%) in [14C]sucrose permeability in RMECs. This increase is reduced 42% by 2 h of posthypoxic reoxygenation (95% room air-5% CO2; Fig. 3). We next determined whether inhibition of PKC altered these responses. The data presented in Fig. 3 show that pretreatment with the PKC inhibitor chelerythrine chloride (10 µM; 15 min) before H (1% O2-99% N2; 24 h) significantly attenuates the H-induced increase in [14C]sucrose permeability in RMECs. Reoxygenation (95% room air-5% CO2; 2 h) following treatment with H (1% O2; 24 h) and chelerythrine chloride (C; 10 µM; 15 min) did reduce [14C]sucrose permeability similar to H/R alone (Fig. 3). However, the effects of PKC inhibition and H/R on [14C]sucrose permeability were not additive (Fig. 3). When compared with normoxic controls (95% room air-5% CO2; 24 h), chelerythrine chloride (10 µM; 15 min) had no effect on RMEC paracellular permeability to [14C]sucrose (Fig. 3).



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 3. Hypoxia-induced paracellular permeability changes are attenuated by PKC inhibition. Confluent monolayers of cultured RMECs were treated with either general PKC inhibitor chelerythrine chloride (C; 10 µM, 15 min) or phosphate-buffered saline (20 µl) and then exposed to normoxia (N, room air, 24 h), hypoxia (H, 1% O2-99% N2; 24 h) or hypoxia followed by 2 h of posthypoxic reoxygenation (H/R, room air), and paracellular permeability was determined as described in MATERIALS AND METHODS. Graph shows means ± SE for treatment conditions. *P < 0.05 compared with N; §P < 0.05 compared with H (n = 8–12).

 
H alters BBB endothelial cell PKC activity expression in vivo. We next wanted to determine whether PKC activity was also altered in our global, nonocclusive in vivo H model. Similar to what was found in the in vitro RMEC model, H stimulated PKC activity dramatically in isolated RCMV from rats treated with H (6% O2-94% N2; 1 h; Fig. 4) compared with that of normoxia controls (room air; 1 h). Reoxygenation for 10 min in room air attenuated the increase in PKC activity in the nonocclusive in vivo BBB model back toward normoxic control levels (Fig. 4).



View larger version (9K):
[in this window]
[in a new window]
  		Fig. 4. Hypoxia stimulates total PKC activity in vivo. Sprague-Dawley rats were exposed to normoxia (N, room air, 1 h), hypoxia (H, 6% O2-94% N2; 1 h), or hypoxia followed by 10 min of posthypoxic reoxygenation (H/R, room air, 10 min). Rat cerebral microvessels (RCMV) were isolated, and total PKC activity was measured as described in MATERIALS AND METHODS. Graph shows means ± SE for treatment conditions. *P < 0.05 compared with N; §P < 0.05 compared with H (n = 7–9).

 
H and H/R alterations in PKC isozyme expression in vivo. Because PKC activity also increased in our nonocclusive in vivo model, we also investigated the effects of H and H/R on PKC isozyme expression in isolated RCMV. Similar to what was found in vitro, expression of PKC-{gamma} significantly increased after H (6% O2-94% N2; 1 h) and remained elevated following H/R (room air; Fig. 5A). In addition, there is a trend for an increase in PKC-{beta}II expression after H and H/R in vivo. However, the increase was not statistically significant. As seen in RMECs, there was no affect of H or H/R on PKC-{alpha} and PKC-{beta}I expression in the in vivo BBB model (Table 2). Additionally, the expression of the novel and atypical PKC isozymes was quite different in the in vivo model compared with the in vitro model. There was only an increase in PKC-{theta} after H/R in the in vivo model (Fig. 5B; Table 2). Furthermore, PKC-{lambda} was unable to be detected in isolated RCMV (Table 2).



View larger version (64K):
[in this window]
[in a new window]
  		Fig. 5. Hypoxia and posthypoxic reoxygenation alter protein expression of PKC isozymes PKC-{gamma} and PKC-{theta} in isolated RCMV. Sprague-Dawley rats were exposed to normoxia (N, room air, 1 h), hypoxia (H, 6% O2-94% N2; 1 h), or hypoxia followed by 10 min of posthypoxic reoxygenation (H/R, room air, 10 min), and protein expression was measured using Western blot analysis. Representative Western blot analysis showing expression of the conventional PKC isozymes (A; {alpha}, {beta}I, {beta}II, and {gamma}), novel PKC isozymes (B; µ, {epsilon}, {eta}, {delta}, and {theta}), and atypical PKC isozyme (C; {zeta}) after treatment conditions. Atypical PKC isozyme PKC-{lambda} was not detected by Western blot analysis. Table 2 summarizes the data from all Western blot analyses.

 

View this table:
[in this window]
[in a new window]
  		Table 2. Effects of H and H/R on protein expression of conventional, novel, and atypical PKC isozymes in vivo

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
The data presented here demonstrate that PKC is involved in the paracellular permeability changes induced by H and H/R. Stimulation of total PKC activity by H and H/R in BBB endothelial cells correlates with BBB paracellular permeability changes induced by H and H/R. Moreover, inhibition of PKC attenuates the H-induced increase in [14C]sucrose permeability. The specific PKC isozymes involved in the H-induced paracellular permeability changes remain to be determined. However, results from the present study show that H and H/R regulate the expression of multiple isozymes of PKC, suggesting these isozymes may be mediating the effects of H and H/R on paracellular permeability.

One mechanism by which H and H/R may increase total PKC activity is enhanced PKC protein expression. There are 11 isozymes of PKC that are categorized based on their modes of activation. The conventional PKCs ({alpha}, {beta}I, {beta}II, {gamma}) require Ca2+, whereas the novel (µ, {epsilon}, {eta}, {delta}, {theta}) and the atypical ({zeta},{lambda}) PKCs are Ca2+ independent (28, 30). Although previous studies (32, 37) have shown the expression of at least 6 PKC isozymes ({alpha}, {beta}, {delta}, {epsilon}, {eta}, {zeta}) in endothelial cells, the data presented here demonstrate that all 11 isozymes of PKC are expressed in BBB endothelial cells in vitro (Table 1), and 10 PKC isozymes are expressed in vivo (Table 2). Neither of the previous studies investigated the expression of PKC-µ, PKC-{theta}, and PKC-{lambda}. More of a surprise, however, is the fact that PKC-{gamma} is expressed in BBB endothelial cells because both of the previous studies (32, 37) were unable to detect this isozyme in endothelial cells. This could be due to the development of more specific antibodies for the various PKC isozymes, or it could be explained by differences in the endothelial cell models. For example, the first study used a cultured human umbilical vein endothelial cell line (HUVEC) and was unable to detect both PKC-{delta} and PKC-{gamma} while detecting four other PKC isozymes (37). The second study used an immortalized cell line, rat brain endothelial-4 (RBE4), isolated RMECs from 2-wk-old rats, aortic endothelial cells, and isolated cerebral capillaries, and they were able to detect six PKC isozymes but not PKC-{gamma} (32).

Because the expression of some of the PKC isoforms remains elevated even as PKC activity levels are decreasing and the fact that the expression of some PKC isoforms do not increase until PKC activity levels are decreasing suggest that other intracellular mechanisms besides increased protein expression may be involved in regulating PKC activity. Additionally, the large increases in PKC activity most likely cannot be explained by only increased protein expression. This suggests that PKC is being altered by other intracellular mechanisms. For example, it has been shown that activated PKC translocates from the cytoplasm to the membrane once it is activated (41). Furthermore, PKC itself is phosphorylated on activation (41). Although these studies focused on the changes in PKC isozyme protein expression, it is important to note that there is most likely an increase in translocation and/or phosphorylation of the various PKC isozymes. Future studies will be required to determine the activation (translocation and/or phosphorylation) of the individual PKC isozymes and their role in regulating BBB function.

The results from the present experiments are supported by previous studies showing that PKC regulates cell permeability in both endothelial and epithelial cells. For example, it has been shown that anoxia stimulates an increase in PKC activity and expression but not PKA activity and expression in cultured brain endothelial cells (26). Also, PKC-{alpha} and PKC-{beta} have both been implicated in regulating cell permeability after ischemia and inflammatory stimuli (49). However, some of the most compelling evidence comes from studies (5, 6, 12, 14) in which it was shown that PKC-{delta}, PKC-{theta}, and PKC-{lambda} all play a role in mediating epithelial cell integrity. More specifically, these studies demonstrated that disruption of epithelial barrier integrity by oxidants involves upregulation of PKC-{delta}, which in turn modulates inducible NO synthase (iNOS) (6). Additionally, in vivo studies (15) have indicated that PKC-{delta} mediates injury caused by cerebral reperfusion. Although our results do not show an increase in PKC-{delta} expression, our results do not exclude the possibility that PKC-{delta} may play a role in altering BBB endothelial cell integrity during H and H/R. Also, our data, which show an increase in PKC-{lambda} expression in RMECs, suggest that this may be one isozyme that is important in regulating endothelial barrier integrity.

Although our study along with the literature suggests a role for PKC in the detrimental effects of H on BBB function, we cannot exclude the possibility that the activation of PKC may protect BBB integrity as was found in epithelial cells. Recently, it has been shown that the protective effect of EGF on intestinal barrier integrity during exposure to oxidants is due to the activation of PKC-{beta}I and PKC-{zeta} isozymes, which appears to prevent the activation of the transcription factor NF-{kappa}B and degradation of its endogenous inhibitor I-{kappa}B by oxidants (7–10, 13). Another study (11) has shown that the upregulation of iNOS following stimulation by oxidants in epithelial cells is inhibited by the overexpression of PKC-{zeta}, and this leads to the protection of the epithelial barrier integrity. If PKC is important for protecting barrier integrity, it may explain why an increase in the expression of PKC-{zeta}, PKC-{epsilon}, and PKC-{theta} was not observed until H/R, a point when endothelial cell paracellular permeability is returning to basal levels. Although our study did not show an increase in total PKC activity after H/R, we cannot exclude the possibility that PKC-{zeta}, PKC-{epsilon}, and PKC-{theta} activity is upregulated after reoxygenation. Actually, it may be that H/R (in our model system) increases PKC-{zeta}, as well as PKC-{epsilon} and PKC-{theta}, expression (and possibly activity) to reestablish the integrity of the BBB. There are several possible mechanisms by which H/R and PKC-{zeta} may be restoring BBB integrity. Previous studies (35) have shown that inhibition of iNOS attenuates H-induced increases in paracellular permeability and that iNOS expression increases with H and returns to normoxic levels after H/R. This suggests that H/R may be lowering iNOS protein levels by stimulating an increase in PKC-{zeta} expression. This reduction in iNOS could then be contributing to the effect of H/R on [14C]sucrose permeability. A second mechanism by which PKC-{zeta} may protect the BBB is by regulating NF-{kappa}B expression and activity, since previous studies (18, 48) have shown that these are altered at the BBB during H and H/R.

The one PKC isozyme that demonstrated a significant change in both our in vitro and in vivo models was PKC-{gamma}. In addition, there were similar trends in the upregulation of PKC-{beta}II both in vitro and in vivo. As stated earlier, cell permeability changes after ischemia and inflammatory stimulation are regulated by PKC-{beta} (49). On the other hand, little is known about the function of PKC-{gamma} in endothelial cells, because previous studies (32, 37) demonstrated a lack of expression of this isozyme. However, studies (17) have shown that H-mediated changes in endothelial cell permeability involve alterations in intracellular Ca2+. Additionally, studies (16) have implicated a role for Ca2+ in modulating occludin expression and localization after hypoxic stress. Because both PKC{beta}-II and PKC-{gamma} are categorized as conventional PKCs (28, 30), this suggests that PKC-{beta}II and PKC-{gamma}, in conjunction with changes in intracellular Ca2+, may be contributing to H-induced changes in paracellular permeability. Future studies are needed to investigate whether these two PKC isozymes are involved in the observed Ca2+-dependent alterations.

There are several possible mechanisms by which PKC may be altering BBB permeability. One possible mechanism is direct regulation (phosphorylation) of the TJ proteins by PKC. PKC-{zeta} has been shown to colocalize with zonula occludens (ZO-1) in Madin-Darby canine kidney (MDCK) and human caucasian colon adenocarcinoma-2 (Caco-2) cell lines (22). It has also been shown that occludin phosphorylation can alter its interactions with intracellular scaffolding proteins (33). This supports the hypothesis that PKC may directly regulate the structure and function of TJ proteins. Furthermore, studies (44, 45) have shown that the activation of PKC-{alpha} disrupts the TJ and causes disassembly of occludin at the TJ. Another hypothesis is that PKC may be indirectly altering the TJ proteins by activating a downstream intracellular signaling pathway that in turn directly affects the TJ proteins. Previous studies (17, 18) have demonstrated that changes in NO and intracellular Ca2+ contribute to increases in paracellular permeability induced by H and H/R. Increases in the expression of the Ca2+-dependent isozymes PKC-{beta}II and PKC-{gamma} along with PKC-{zeta}, which can regulate NOS (5), suggest that PKC may interact with this signaling molecule to contribute to BBB permeability alterations.

A final hypothesis to consider is that PKC may not alter the TJ proteins but affects other proteins located at the endothelial cell junction to regulate paracellular permeability. This idea is supported by a study (20) that showed that PKC mediates BBB function by altering ICAM and fluid phase endocytosis in tumor necrosis factor {alpha}-treated endothelial cells. It is also supported by a study (24) that demonstrated a minimal role for PKC in H-induced BBB permeability and TJ alterations induced by H and VEGF.

The unique aspect of the present study is our attempt to translate our results from the in vitro BBB model to our nonocclusive, global in vivo hypoxia model. It was interesting to note that in both models there was a significant increase in PKC activity after treatment with H and that this increase was reduced during H/R. Also of interest were the differences in the expression of the various PKC isozymes during the different treatment conditions in both models. In the in vitro H model, the protein expression of 7 of 11 PKC isozymes was altered after either H and/or H/R. However, the protein expression of only 2 of the 11 PKC isozymes was significantly changed after H and/or H/R in the nonocclusive in vivo hypoxia model. There are several possible explanations for these differences. It could be due to the fact that the in vitro model is a monolayer of endothelial cells. This model is simplified and allows the investigator to study in great detail the response of only the endothelial cells to an insult. However, it is now understood that the endothelial cells, pericytes, glia, and even neurons, all contribute to maintaining the integrity of the BBB as a neurovascular unit (34, 39). This suggests that nonendothelial cells or factors released by these cells can also regulate PKC activity that in turn modulates BBB function. It also implies that endothelial cells in the in vitro model may be more sensitive to H and H/R due to the lack of pericytes, glia, and neurons, which constitute the intact neurovascular unit. This concept is supported by studies (2, 27, 42, 43) that show that endothelial cells co-cultured with glia and/or neurons respond differently to stimuli than do endothelial cells cultured alone. A second explanation for the differences between the in vitro and in vivo H models may be the level of H and duration of the hypoxic exposure. The Davis laboratory (35, 36, 47) fully characterized both models in previous studies, and the O2 levels and H duration were based on points where functional (paracellular permeability) changes in the BBB were observed. However, it may be that the in vitro and in vivo regulation of PKC activity and protein expression is different based on the levels of O2 and the duration of exposure.

In conclusion, this study demonstrates that the H-induced increases in PKC activity in BBB endothelial cells play a functional role in altering [14C]sucrose paracellular permeability. This study also shows for the first time that all 11 PKC isozymes are present in BBB endothelial cells. Furthermore, the results indicate that the expression of various isozymes of PKC is differentially regulated by H and H/R. These data suggest that different PKC isozymes may contribute to different cellular functions leading to alterations in endothelial cell integrity during physiological and pathophysiological states.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported by a Postdoctoral National Research Service Award F32-NS-049894 (to M. A. Fleegal) and by RO1-NS-39592 (to T. P. Davis).


   FOOTNOTES
 

Address for reprint requests and other correspondence: T. P. Davis, Dept. of Medical Pharmacology, College of Medicine, The Univ. of Arizona, 1501 N. Campbell Ave., Tucson, AZ 85724 (e-mail: davistp{at}u.arizona.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Abbruscato TJ and Davis TP. Combination of hypoxia/aglycemia compromises in vitro blood-brain barrier integrity. J Pharmacol Exp Ther 289: 668–675, 1999.[Abstract/Free Full Text]
  2. Abbruscato TJ and Davis TP. Protein expression of brain endothelial cell E-cadherin after hypoxia/aglycemia: influence of astrocyte contact. Brain Res 842: 277–286, 1999.[CrossRef][Web of Science][Medline]
  3. Akopov S and Cohen SN. Preventing stroke: a review of current guidelines. J Am Med Dir Assoc 4: S127–S132, 2003.[CrossRef][Medline]
  4. Andreeva AY, Krause E, Muller EC, Blasig IE, and Utepbergenov DI. Protein kinase C regulates the phosphorylation and cellular localization of occludin. J Biol Chem 276: 38480–38486, 2001.[Abstract/Free Full Text]
  5. Banan A, Farhadi A, Fields JZ, Zhang LJ, Shaikh M, and Keshavarzian A. The delta-isoform of protein kinase C causes inducible nitric-oxide synthase and nitric oxide up-regulation: key mechanism for oxidant-induced carbonylation, nitration, and disassembly of the microtubule cytoskeleton and hyperpermeability of barrier of intestinal epithelia. J Pharmacol Exp Ther 305: 482–494, 2003.[Abstract/Free Full Text]
  6. Banan A, Fields JZ, Farhadi A, Talmage DA, Zhang L, and Keshavarzian A. Activation of delta-isoform of protein kinase C is required for oxidant-induced disruption of both the microtubule cytoskeleton and permeability barrier of intestinal epithelia. J Pharmacol Exp Ther 303: 17–28, 2002.[Abstract/Free Full Text]
  7. Banan A, Fields JZ, Farhadi A, Talmage DA, Zhang L, and Keshavarzian A. The beta 1 isoform of protein kinase C mediates the protective effects of epidermal growth factor on the dynamic assembly of F-actin cytoskeleton and normalization of calcium homeostasis in human colonic cells. J Pharmacol Exp Ther 301: 852–866, 2002.[Abstract/Free Full Text]
  8. Banan A, Fields JZ, Talmage DA, Zhang L, and Keshavarzian A. PKC-{zeta} is required in EGF protection of microtubules and intestinal barrier integrity against oxidant injury. Am J Physiol Gastrointest Liver Physiol 282: G794–G808, 2002.[Abstract/Free Full Text]
  9. Banan A, Fields JZ, Talmage DA, Zhang Y, and Keshavarzian A. PKC-{beta}1 mediates EGF protection of microtubules and barrier of intestinal monolayers against oxidants. Am J Physiol Gastrointest Liver Physiol 281: G833–G847, 2001.[Abstract/Free Full Text]
  10. Banan A, Fields JZ, Zhang LJ, Shaikh M, Farhadi A, and Keshavarzian A. Zeta isoform of protein kinase C prevents oxidant-induced nuclear factor-kappaB activation and I-kappaBalpha degradation: a fundamental mechanism for epidermal growth factor protection of the microtubule cytoskeleton and intestinal barrier integrity. J Pharmacol Exp Ther 307: 53–66, 2003.[Abstract/Free Full Text]
  11. Banan A, Zhang L, Fields JZ, Farhadi A, Talmage DA, and Keshavarzian A. PKC-{zeta} prevents oxidant-induced iNOS upregulation and protects the microtubules and gut barrier integrity. Am J Physiol Gastrointest Liver Physiol 283: G909–G922, 2002.[Abstract/Free Full Text]
  12. Banan A, Zhang LJ, Farhadi A, Fields JZ, Shaikh M, Forsyth CB, Choudhary S, and Keshavarzian A. Critical role of the atypical (lambda) isoform of protein kinase C [PKC-(lambda)] in oxidant-induced disruption of the microtubule cytoskeleton and barrier function of intestinal epithelium. J Pharmacol Exp Ther 312: 458–471, 2005.[Abstract/Free Full Text]
  13. Banan A, Zhang LJ, Farhadi A, Fields JZ, Shaikh M, and Keshavarzian A. PKC-{beta}1 isoform activation is required for EGF-induced NF-{kappa}B inactivation and I{kappa}B{alpha} stabilization and protection of F-actin assembly and barrier function in enterocyte monolayers. Am J Physiol Cell Physiol 286: C723–C738, 2004.[Abstract/Free Full Text]
  14. Banan A, Zhang LJ, Shaikh M, Fields JZ, Farhadi A, and Keshavarzian A. Theta-isoform of PKC is required for alterations in cytoskeletal dynamics and barrier permeability in intestinal epithelium: a novel function for PKC-{theta}. Am J Physiol Cell Physiol 287: C218–C234, 2004.[Abstract/Free Full Text]
  15. Bright R, Raval AP, Dembner JM, Perez-Pinzon MA, Steinberg GK, Yenari MA, and Mochly-Rosen D. Protein kinase C delta mediates cerebral reperfusion injury in vivo. J Neurosci 24: 6880–6888, 2004.[Abstract/Free Full Text]
  16. Brown RC and Davis TP. Hypoxia/aglycemia alters expression of occludin and actin in brain endothelial cells. Biochem Biophys Res Commun 327: 1114–1123, 2005.[CrossRef][Web of Science][Medline]
  17. Brown RC, Mark KS, Egleton RD, and Davis TP. Protection against hypoxia-induced blood-brain barrier disruption: changes in intracellular calcium. Am J Physiol Cell Physiol 286: C1045–C1052, 2004.[Abstract/Free Full Text]
  18. Brown RC, Mark KS, Egleton RD, Huber JD, Burroughs AR, and Davis TP. Protection against hypoxia-induced increase in blood-brain barrier permeability: role of tight junction proteins and NFkappaB. J Cell Sci 116: 693–700, 2003.[Abstract/Free Full Text]
  19. Bruckener KE, el Baya A, Galla HJ, and Schmidt MA. Permeabilization in a cerebral endothelial barrier model by pertussis toxin involves the PKC effector pathway and is abolished by elevated levels of cAMP. J Cell Sci 116: 1837–1846, 2003.[Abstract/Free Full Text]
  20. Defazio G, Nico B, Trojano M, Ribatti D, Giorelli M, Ricchiuti F, Martino D, Roncali L, and Livrea P. Inhibition of protein kinase C counteracts TNFalpha-induced intercellular adhesion molecule 1 expression and fluid phase endocytosis on brain microvascular endothelial cells. Brain Res 863: 245–248, 2000.[CrossRef][Web of Science][Medline]
  21. Desai TR, Leeper NJ, Hynes KL, and Gewertz BL. Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J Surg Res 104: 118–123, 2002.[CrossRef][Web of Science][Medline]
  22. Dodane V and Kachar B. Identification of isoforms of G proteins and PKC that colocalize with tight junctions. J Membr Biol 149: 199–209, 1996.[CrossRef][Web of Science][Medline]
  23. Farshori P and Kachar B. Redistribution and phosphorylation of occludin during opening and resealing of tight junctions in cultured epithelial cells. J Membr Biol 170: 147–156, 1999.[CrossRef][Web of Science][Medline]
  24. Fischer S, Wiesnet M, Marti HH, Renz D, and Schaper W. Simultaneous activation of several second messengers in hypoxia-induced hyperpermeability of brain derived endothelial cells. J Cell Physiol 198: 359–369, 2004.[CrossRef][Web of Science][Medline]
  25. Fleegal MA and Sumners C. Drinking behavior elicited by central injection of angiotensin II: roles for protein kinase C and Ca2+/calmodulin-dependent protein kinase II. Am J Physiol Regul Integr Comp Physiol 285: R632–R640, 2003.[Abstract/Free Full Text]
  26. Grammas P, Moore P, Cashman RE, and Floyd RA. Anoxic injury of endothelial cells causes divergent changes in protein kinase C and protein kinase A signaling pathways. Mol Chem Neuropathol 33: 113–124, 1998.[Web of Science][Medline]
  27. Hayashi K, Nakao S, Nakaoke R, Nakagawa S, Kitagawa N, and Niwa M. Effects of hypoxia on endothelial/pericytic co-culture model of the blood-brain barrier. Regul Pept 123: 77–83, 2004.[CrossRef][Web of Science][Medline]
  28. Hofmann J. The potential for isoenzyme-selective modulation of protein kinase C. FASEB J 11: 649–669, 1997.[Abstract]
  29. Huber JD, Egleton RD, and Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 24: 719–725, 2001.[CrossRef][Web of Science][Medline]
  30. Jaken S. Protein kinase C isozymes and substrates. Curr Opin Cell Biol 8: 168–173, 1996.[CrossRef][Web of Science][Medline]
  31. Kniesel U and Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 20: 57–76, 2000.[CrossRef][Web of Science][Medline]
  32. Krizbai I, Szabo G, Deli M, Maderspach K, Lehel C, Olah Z, Wolff JR, and Joo F. Expression of protein kinase C family members in the cerebral endothelial cells. J Neurochem 65: 459–462, 1995.[Web of Science][Medline]
  33. Krizbai IA and Deli MA. Signalling pathways regulating the tight junction permeability in the blood-brain barrier. Cell Mol Biol (Noisy-le-grand) 49: 23–31, 2003.[Medline]
  34. Lo EH, Broderick JP, and Moskowitz MA. tPA and proteolysis in the neurovascular unit. Stroke 35: 354–356, 2004.[Free Full Text]
  35. Mark KS, Burroughs AR, Brown RC, Huber JD, and Davis TP. Nitric oxide mediates hypoxia-induced changes in paracellular permeability of cerebral microvasculature. Am J Physiol Heart Circ Physiol 286: H174–H180, 2004.[Abstract/Free Full Text]
  36. Mark KS and Davis TP. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 282: H1485–H1494, 2002.[Abstract/Free Full Text]
  37. Mattila P, Majuri ML, Tiisala S, and Renkonen R. Expression of six protein kinase C isotypes in endothelial cells. Life Sci 55: 1253–1260, 1994.[CrossRef][Web of Science][Medline]
  38. Miller DW, Audus KL, and Borchardt RT. Application of Cultured Endothelial Cells of the Brain Microvasculature in the Study of the Blood-Brain Barrier. J Tiss Cult Meth 14: 217–224, 1992.[CrossRef]
  39. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery 54: 131–142, 2004.[CrossRef][Web of Science][Medline]
  40. Pardridge WM. Molecular biology of the blood-brain barrier. Methods Mol Med 89: 385–399, 2003.[Medline]
  41. Ron D and Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 13: 1658–1676, 1999.[Abstract/Free Full Text]
  42. Savettieri G, Di Liegro I, Catania C, Licata L, Pitarresi GL, D'Agostino S, Schiera G, De Caro V, Giandalia G, Giannola LI, and Cestelli A. Neurons and ECM regulate occludin localization in brain endothelial cells. Neuroreport 11: 1081–1084, 2000.[Web of Science][Medline]
  43. Schiera G, Bono E, Raffa MP, Gallo A, Pitarresi GL, Di Liegro I, and Savettieri G. Synergistic effects of neurons and astrocytes on the differentiation of brain capillary endothelial cells in culture. J Cell Mol Med 7: 165–170, 2003.[Web of Science][Medline]
  44. Schmitt M, Horbach A, Kubitz R, Frilling A, and Haussinger D. Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol 41: 274–283, 2004.[CrossRef][Web of Science][Medline]
  45. Smith JM, Dornish M, and Wood EJ. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials 26: 3269–3276, 2005.[CrossRef][Web of Science][Medline]
  46. Tsukamoto T and Nigam SK. Role of tyrosine phosphorylation in the reassembly of occludin and other tight junction proteins. Am J Physiol Renal Physiol 276: F737–F750, 1999.[Abstract/Free Full Text]
  47. Witt KA, Mark KS, Hom S, and Davis TP. Effect of hypoxia/reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 285: H2820–H2831, 2003.[Abstract/Free Full Text]
  48. Witt KA, Mark KS, Huber J, and Davis TP. Hypoxia-inducible factor and nuclear factor kappa-B activation in blood-brain barrier endothelium under hypoxic/reoxygenation stress. J Neurochem 92: 203–214, 2005.[CrossRef][Web of Science][Medline]
  49. Yuan SY. Protein kinase signaling in the modulation of microvascular permeability. Vascul Pharmacol 39: 213–223, 2002.[CrossRef][Web of Science][Medline]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
Y. Sonobe, H. Takeuchi, K. Kataoka, H. Li, S. Jin, M. Mimuro, Y. Hashizume, Y. Sano, T. Kanda, T. Mizuno, et al.
Interleukin-25 Expressed by Brain Capillary Endothelial Cells Maintains Blood-Brain Barrier Function in a Protein Kinase C{epsilon}-dependent Manner
J. Biol. Chem., November 13, 2009; 284(46): 31834 - 31842.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/5/H2012    most recent
00495.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleegal, M. A.
Right arrow Articles by Davis, T. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fleegal, M. A.
Right arrow Articles by Davis, T. P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.